A hun­gry Take­da con­tin­ues deal spree with $125M T cell pact, op­tion to buy

Take­da is on a tear.

Two days af­ter an­nounc­ing a $5.2 bil­lion deal to ac­quire Ari­ad, the glob­al Japan­ese phar­ma com­pa­ny is back with the lat­est in a string of small­er pacts, in­vest­ing $125 mil­lion in Mav­er­ick Ther­a­peu­tics and pick­ing up an op­tion to buy the biotech and its T cell en­gage­ment plat­form.

The cash comes for an up­front pay­ment, eq­ui­ty stake and R&D sup­port, with Take­da step­ping in­to a $23 mil­lion Se­ries B to help fu­el the next round of de­vel­op­ment. Take­da and Mav­er­ick, an MPM Cap­i­tal com­pa­ny, have al­ready worked out a buy­out price for five years down the road, but they aren’t dis­clos­ing it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER